Print Version |
Net sales during the three months ended
CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 77.1% to
Based on our current sales order volumes, backlog and forecasts we have received from our customers; we now anticipate our fiscal year 2022 consolidated net sales will increase between 7.0% and 10.0% as compared to fiscal year 2021. We also now anticipate we will generate operating income between 10.0% and 13.0% of net sales for our fiscal year ending
As of
"We continue to navigate challenges related to supply chain and staffing that have resulted in larger than normal backlog, but we believe we will be able to overcome these challenges by the end of this calendar year. Our investments related to securing adequate supplies of inventory and labor are expected to pay dividends in the second half of our current fiscal year."
"We believe our favorable profitability as a percentage of sales is a trend that will be fully realized on a full year basis supported by improved customer mix, capacity utilization, favorable currency translation on foreign sales, and improved contribution from our CarnoSyn® business."
An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/).
NAI, headquartered in
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, our ability to attract and retain sufficient labor, COVID-19 and related impacts on the availability of raw materials, our future revenue profits and financial condition, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the
CONTACT –
Web site: http://www.nai-online.com
|
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
||||||||
(In thousands, except per share data) |
||||||||
(Unaudited) |
||||||||
Three Months Ended |
||||||||
|
||||||||
2021 |
2020 |
|||||||
|
$ 38,340 |
100.0% |
$ 39,726 |
100.0% |
||||
Cost of goods sold |
30,059 |
78.4% |
33,721 |
84.9% |
||||
Gross profit |
8,281 |
21.6% |
6,005 |
15.1% |
||||
Selling, general & administrative expenses |
4,053 |
10.6% |
3,920 |
9.9% |
||||
INCOME FROM OPERATIONS |
4,228 |
11.0% |
2,085 |
5.2% |
||||
Other expense, net |
(26) |
-0.1% |
(321) |
-0.8% |
||||
INCOME BEFORE TAXES |
4,202 |
11.0% |
1,764 |
4.4% |
||||
Income tax expense (benefit) |
946 |
(494) |
||||||
NET INCOME |
$ 3,256 |
$ 2,258 |
||||||
NET INCOME PER COMMON SHARE: |
||||||||
Basic: |
|
|
||||||
Diluted: |
|
|
||||||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: |
||||||||
Basic |
6,288 |
6,418 |
||||||
Diluted |
6,351 |
6,471 |
||||||
|
|||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||
(In thousands) |
|||
(unaudited) |
|||
|
|
||
2021 |
2021 |
||
ASSETS |
|||
Cash and cash equivalents |
|
|
|
Accounts receivable, net |
20,245 |
17,946 |
|
Inventories, net |
31,709 |
27,006 |
|
Other current assets |
3,254 |
3,263 |
|
Total current assets |
75,236 |
80,348 |
|
Property and equipment, net |
39,504 |
22,271 |
|
Operating lease right-of-use assets |
15,212 |
15,877 |
|
Other noncurrent assets, net |
2,211 |
1,785 |
|
Total Assets |
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||
Accounts payable and accrued liabilities |
21,921 |
23,717 |
|
Line of credit |
10,000 |
- |
|
Long-term liability - operating leases |
15,737 |
16,481 |
|
Total Liabilities |
47,658 |
40,198 |
|
Stockholders' Equity |
84,505 |
80,083 |
|
Total Liabilities and Stockholders' Equity |
|
|
|
View original content:https://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-2022-q1-results-301420305.html
SOURCE